In the case of AD, this includes structural, functional, and molecular imaging, as well as measurements of signature proteins in the cerebrospinal fluid (CSF), i.e. amyloid-β (Aβ) and tau isoforms (Livingston et al. 2017; G. M. McKhann et al. 2011). The gene discussed is MAPT; the disease is Alzheimer disease.